List of Excipients in Branded Drug CARBIDOPA TABLETS, 25 MG

Generic Drugs Containing CARBIDOPA TABLETS, 25 MG

Company	Ingredient	NDC	Excipient
Alvogen Inc	carbidopa tablets, 25 mg	47781-332	CELLULOSE, MICROCRYSTALLINE
Alvogen Inc	carbidopa tablets, 25 mg	47781-332	FD&C YELLOW NO. 6
Alvogen Inc	carbidopa tablets, 25 mg	47781-332	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in CARBIDOPA TABLETS, 25 MG?

# Of NDCs	Excipient
2	CELLULOSE, MICROCRYSTALLINE
2	FD&C YELLOW NO. 6
2	MAGNESIUM STEARATE

Carbidopa Tablets 25 mg: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 18, 2026

Carbidopa 25 mg tablets are mature, immediate-release, small-molecule products with limited patent barriers and modest formulation complexity. Commercial value is concentrated in reliable supply, low-cost manufacturing, tablet robustness, excipient tolerability, packaging, and differentiated distribution rather than exclusivity. The strongest opportunities are generic supply, levodopa-carbidopa regimen support, hospital and long-term-care contracts, and reformulation for patients with excipient sensitivities or swallowing difficulties.

What is the regulatory status of carbidopa 25 mg tablets?

Carbidopa is an aromatic amino-acid decarboxylase inhibitor used with levodopa in Parkinson's disease and related movement disorders. It reduces peripheral conversion of levodopa to dopamine, increasing the amount of levodopa reaching the brain and reducing peripheral adverse effects.

The 25 mg tablet is used primarily with immediate-release levodopa or levodopa-carbidopa therapy. In the United States, carbidopa tablets are approved through the FDA's abbreviated new drug application pathway when the product demonstrates pharmaceutical equivalence and bioequivalence to the applicable reference product.[1]

Product characteristic	Commercial assessment
Active ingredient	Carbidopa
Strength	25 mg per tablet
Dosage form	Immediate-release oral tablet
Therapeutic area	Parkinson's disease and parkinsonism
Regulatory pathway	ANDA for generic products
Biologic status	Not applicable
Biosimilar pathway	Not applicable
Primary reference product	Lodosyn, where applicable
Main combination product	Levodopa/carbidopa tablets
Patent value	Low for the active ingredient; formulation and process value may remain
Main commercial barriers	Manufacturing cost, quality consistency, supply reliability, reimbursement

Carbidopa tablets are often prescribed as part of a levodopa-carbidopa regimen rather than as a high-value standalone therapy. That use pattern limits pricing power but creates recurring demand from neurologists, hospitals, pharmacies, and long-term-care providers.

What excipients are used in carbidopa 25 mg tablets?

Published labels for carbidopa tablet products generally identify conventional immediate-release tablet excipients, including diluents, disintegrants, binders, lubricants, and, in some products, coloring agents.[2][3]

The exact qualitative and quantitative composition differs by manufacturer. A representative excipient architecture may include:

Excipient function	Candidate excipients	Commercial purpose
Diluent	Microcrystalline cellulose, lactose, starch	Provides tablet mass and compressibility
Binder	Povidone, pregelatinized starch	Improves granulation and mechanical strength
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Promotes tablet breakup and dissolution
Lubricant	Magnesium stearate, stearic acid	Reduces punch adhesion and ejection force
Glidant	Colloidal silicon dioxide	Improves powder flow
Colorant	Approved FD&C or D&C colorants	Supports product identification
Opacifier	Titanium dioxide, where used	Provides visual uniformity
Coating materials	Hypromellose, polyethylene glycol, talc	Improves handling and swallowability

Excipient selection must account for carbidopa's low dose relative to total tablet weight. A 25 mg active load can create content-uniformity and segregation risks if the active ingredient has materially different particle size, density, or flow characteristics from the diluent system.

Which excipient attributes matter most?

The highest-value attributes are:

1. Blend uniformity at low drug loading.
2. Tablet hardness without delayed disintegration.
3. Consistent dissolution across manufacturing lots.
4. Low lubricant sensitivity.
5. Chemical stability under heat and humidity.
6. Acceptable appearance and color consistency.
7. Compatibility with the reference product's dissolution profile.

Carbidopa is susceptible to degradation under unfavorable environmental conditions. Formulators should evaluate water activity, oxygen exposure, light sensitivity, and interaction with alkaline or reactive excipients. Packaging may be as important as the excipient system, particularly where the selected formulation has limited moisture or oxygen tolerance.

What is the best excipient strategy for a generic carbidopa 25 mg tablet?

The lowest-risk strategy is a conventional, direct-compression or dry-granulation formulation using established pharmaceutical excipients. A practical development target is a robust tablet that reaches rapid immediate-release dissolution without relying on novel excipients or complex coating systems.

Strategy A: Microcrystalline cellulose and crospovidone

This approach uses microcrystalline cellulose as the principal filler and dry binder, with crospovidone as the disintegrant. Magnesium stearate and colloidal silicon dioxide may be used at low levels to control lubrication and flow.

Advantages include:

• Established compaction performance.
• Broad supplier availability.
• Compatibility with direct compression.
• Simple manufacturing scale-up.
• Low process complexity.

The main risk is over-lubrication. Excess magnesium stearate can reduce tablet wettability and slow dissolution. The formulation should establish a narrow lubrication window supported by blend-time and dissolution studies.

Strategy B: Lactose and starch-based formulation

Lactose combined with pregelatinized starch or native starch can provide a lower-cost tablet platform. This system may be attractive where the manufacturer has existing lactose-based equipment and validated processes.

Potential limitations include:

• Greater sensitivity to moisture.
• Variable flow depending on lactose grade.
• Possible Maillard-type compatibility concerns with reactive amine-containing compounds.
• Higher risk of batch-to-batch compression variation.

Compatibility screening should test lactose grades, water activity, elevated temperature, and long-term storage. A lactose-free design may also expand access for patients with excipient concerns, although clinically significant lactose intolerance from a small tablet dose is not universal.

Strategy C: Low-excipient, color-free formulation

A color-free, low-excipient tablet can target hospitals, specialty pharmacies, and patients who seek products without synthetic dyes. It can also simplify supply if the formulation eliminates multiple colorants or coating components.

The commercial tradeoff is less visual differentiation. A robust imprint, blister configuration, or packaging system becomes important for medication identification.

Strategy D: Film-coated immediate-release tablet

Film coating can improve swallowability, reduce powdering, and protect the core from handling damage. It also creates an opportunity to differentiate the product without altering the immediate-release profile.

The coating should remain thin and rapidly wettable. A coating that materially delays dissolution could create bioequivalence and product-performance risk. Colorant selection should consider global regulatory restrictions and pharmacy substitution requirements.

What formulation patents protect carbidopa 25 mg tablets?

The active ingredient and basic use of carbidopa are mature technologies. Core composition-of-matter and early therapeutic patents are generally expired or commercially irrelevant in the U.S. market. Current value is more likely to arise from:

• Specific tablet compositions.
• Modified-release dosage forms.
• Combination products with levodopa.
• Stabilized carbidopa formulations.
• Manufacturing processes.
• Particle-size or solid-state controls.
• Packaging systems.
• Nontraditional delivery systems.

A conventional immediate-release 25 mg tablet made from standard excipients is unlikely to support meaningful patent exclusivity unless it has an unusual composition, unexpected stability result, or other non-obvious technical feature.

What patent claims could still be commercially relevant?

Potentially relevant claim categories include:

Claim category	Relevance to a conventional 25 mg tablet
Carbidopa composition of matter	Generally low because of age
Specific excipient ratios	Possible, but requires narrow and defensible claim scope
Stability-enhancing composition	Moderate if supported by strong data
Modified release	High technical differentiation, but higher development risk
Orally disintegrating tablet	Possible product differentiation
Sprinkle or liquid-dispersible formulation	Niche opportunity
Combination with levodopa	Often commercially important, but crowded
Manufacturing process	Can protect know-how and process control
Packaging and moisture protection	More likely trade-secret or design-around value

Patent clearance must cover both the standalone carbidopa tablet and any proposed combination or differentiated dosage form. The absence of a meaningful patent barrier for the basic tablet does not eliminate risk from later patents covering specific formulations or delivery systems.

When does carbidopa 25 mg lose exclusivity?

Carbidopa 25 mg is a legacy product with no meaningful new chemical entity exclusivity remaining. Any remaining commercial exclusivity would depend on product-specific FDA records, including the reference product's listed patents, regulatory exclusivity, and current marketing status.[1][4]

Exclusivity type	Expected position for carbidopa 25 mg
New chemical entity exclusivity	Expired
Orphan exclusivity	Not generally associated with the conventional product
Pediatric exclusivity	No known strategic relevance to the mature tablet
Basic composition patent	Expired or commercially obsolete
Formulation patent	Product-specific; must be reviewed separately
ANDA exclusivity	Potentially relevant only to a qualifying first generic
Biosimilar exclusivity	Not applicable

A generic entrant should not assume that a legacy product has zero legal risk. It should verify the current Orange Book entry, reference-product status, any listed patents, and any FDA regulatory exclusivity before filing or launching.[1]

What is the Orange Book status of carbidopa tablets?

The FDA Orange Book is the controlling public source for approved drug products, therapeutic equivalence evaluations, patent listings, and exclusivity information.[1] Carbidopa 25 mg tablets should be assessed by:

• Active ingredient and strength.
• Dosage form.
• Reference listed drug designation.
• Therapeutic equivalence code.
• Patent listings.
• Regulatory exclusivity.
• Marketing status.

For a mature immediate-release carbidopa tablet, the practical expectation is an ANDA-driven market with limited Orange Book patent exposure. The relevant risk is less likely to be a basic carbidopa patent and more likely to involve an incorrectly selected reference product, a product-specific formulation patent, or a patent covering a combination regimen.

Are Paragraph IV challenges relevant to carbidopa 25 mg?

Paragraph IV certifications remain legally available for an ANDA applicant that believes a listed patent is invalid, unenforceable, or will not be infringed.[5] Their commercial importance depends on whether the reference product has an active Orange Book patent.

For a mature standalone carbidopa tablet:

• A Paragraph IV filing may have limited value if no meaningful patent is listed.
• A Paragraph III certification may be appropriate where a listed patent remains valid but has a defined expiration date.
• A Paragraph IV strategy could matter for a newer formulation or combination product.
• First-filer economics may be limited because the market is small and generic competition can be intense.

The filing decision should be based on expected litigation cost, market size, probability of 180-day exclusivity, and the commercial value of early launch. For a low-revenue standalone tablet, routine Paragraph IV litigation is unlikely to be attractive unless the applicant expects a strong first-filer position or a meaningful formulation market.

What manufacturing and intellectual-property barriers affect commercial entry?

The principal barriers are operational rather than patent-based.

Manufacturing barriers

Carbidopa 25 mg tablets require control of:

• API particle-size distribution.
• Blend segregation.
• Low-dose content uniformity.
• Compression force and tablet hardness.
• Disintegration and dissolution.
• Degradation products.
• Moisture and oxygen exposure.
• Cleaning validation and cross-contamination controls.

A manufacturer can obtain commercial advantage through a stable supply chain for API and excipients, redundant packaging capacity, and a process that minimizes batch rejection.

Intellectual-property barriers

Trade-secret value may exist in:

• Granulation endpoint controls.
• Lubrication timing.
• Blend order and mixing energy.
• Compression tooling.
• In-process sampling plans.
• Moisture-control packaging.
• Stability-indicating analytical methods.

These protections do not block a competitor in the same way as a patent. They can reduce manufacturing cost, improve yield, and support reliable regulatory performance.

What commercial opportunities exist for carbidopa 25 mg tablets?

Generic supply to retail pharmacies

The broadest opportunity is a low-cost, therapeutically equivalent product supplied through wholesalers and pharmacy benefit channels. Success depends on maintaining availability and avoiding backorders. A slightly higher-cost product with dependable supply can win contracts against a lower-priced but unreliable competitor.

Hospital and long-term-care contracts

Hospitals and nursing facilities value:

• Consistent NDC availability.
• Unit-dose packaging.
• Barcoding.
• Short lead times.
• Limited product substitutions.
• Stable pricing.

Blistered or unit-dose presentations can create commercial separation without requiring a new drug-delivery technology.

Patient-access formulation

Potential differentiation includes:

• Dye-free tablets.
• Lactose-free tablets.
• Smaller tablets.
• Film-coated tablets.
• Scored tablets, where permitted by the approved design.
• Moisture-protective blister packs.
• Easy-open packaging for older patients and caregivers.

Any scoring, splitting, or modified labeling claim requires supporting product-performance data and appropriate FDA review.

Combination-regimen support

Carbidopa 25 mg can support titration and individualized levodopa therapy. A manufacturer could pair standalone carbidopa with patient-support services, adherence packaging, or coordinated supply of levodopa products. The regulatory and commercial value would come from the service model and distribution execution, not from exclusivity in the established active ingredient.

International markets

Geographic opportunities may exist in markets where carbidopa availability is inconsistent or where levodopa is supplied without sufficient peripheral decarboxylase inhibition. Regulatory requirements differ by country, and excipient restrictions, labeling rules, reference-product requirements, and local tender systems must be assessed separately.

How does carbidopa compare with competing Parkinson's disease products?

Product	Main commercial role	Differentiation	Patent risk
Carbidopa 25 mg	Standalone adjunct to levodopa therapy	Low cost and dose flexibility	Low for conventional tablet
Levodopa/carbidopa immediate-release	Core oral therapy	Combination convenience	Product-specific
Levodopa/carbidopa extended-release	Fluctuation management	Modified release	Higher formulation complexity
Levodopa/carbidopa/entacapone	Combination regimen	Fewer tablets	Combination-specific
Ropinirole, pramipexole and similar agents	Dopamine agonist alternatives	Different mechanism	Product-specific
Inhaled or infusion therapies	Rescue or advanced therapy	Delivery-system differentiation	Higher regulatory and patent risk

Carbidopa's commercial weakness is its dependence on a broader levodopa treatment plan. Its strength is low development risk, recurring demand, and the ability to support individualized dosing.

What litigation and settlement risks affect the product?

For a legacy standalone tablet, litigation risk is likely to be limited compared with newer extended-release, infusion, inhaled, or combination Parkinson's products. The key review areas are:

1. Current Orange Book patent listings.
2. Patent litigation involving the reference product or proposed formulation.
3. ANDA litigation under the Hatch-Waxman framework.
4. Settlement agreements involving launch dates or licenses.
5. State and federal product-liability matters.
6. FDA manufacturing or quality enforcement actions.

No biosimilar litigation applies because carbidopa is a chemically synthesized small molecule. Any settlement involving a carbidopa product should be evaluated for launch restrictions, authorized-generic arrangements, supply obligations, and geographic limitations.

How strong is the patent estate for carbidopa 25 mg tablets?

The patent estate is weak for a conventional immediate-release product and stronger only where the product introduces technical differentiation.

Estate component	Relative strength
Carbidopa active ingredient	Very low
Conventional immediate-release tablet	Low
New excipient combination	Low to moderate
Stabilized formulation	Moderate if data are strong
Modified-release delivery	Moderate to high
Combination product	Product-specific
Manufacturing know-how	Moderate as trade secret
Packaging innovation	Low to moderate

The commercial thesis should therefore be based on execution, not patent rent. A differentiated formulation can improve margins, but its development cost should be matched against a likely modest market size.

Key Takeaways

• Carbidopa 25 mg tablets are mature, immediate-release generic products.
• The basic active ingredient has little remaining exclusivity value.
• Conventional excipients such as microcrystalline cellulose, starch, lactose, crospovidone, povidone, colloidal silicon dioxide, and magnesium stearate support low-risk development.
• Low-dose content uniformity, dissolution, degradation control, and moisture protection are the main technical issues.
• A color-free, lactose-free, film-coated, unit-dose, or blister-packaged product offers practical differentiation.
• Paragraph IV strategy is likely to have limited value for a conventional standalone tablet unless an active listed patent is identified.
• Biosimilar risk does not apply.
• The strongest commercial opportunities are reliable generic supply, institutional contracts, patient-access packaging, and support for levodopa titration.
• Product-specific Orange Book and litigation review remains central before filing or launch.

References

1. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations, 45th edition: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

2. U.S. National Library of Medicine. (2025). DailyMed: Carbidopa tablet labeling. https://dailymed.nlm.nih.gov/dailymed/

3. U.S. National Library of Medicine. (2025). DailyMed: Lodosyn carbidopa tablet labeling. https://dailymed.nlm.nih.gov/dailymed/

4. U.S. Food and Drug Administration. (2025). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/

5. U.S. Food and Drug Administration. (2015). Abbreviated new drug application submissions: Refuse-to-receive standards guidance for industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/abbreviated-new-drug-application-submissions-refuse-receive-standards-guidance-industry